
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" lang="de-DE">

	<head profile="http://gmpg.org/xfn/11">
		<meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
		<title> GAPVAC</title>
		<link rel="stylesheet" href="http://gapvac.eu/dev/wp-content/themes/gapvac/style.css" type="text/css" media="screen" />
		<link rel="alternate" type="application/rss+xml" title="GAPVAC &raquo; Startseite Kommentar-Feed" href="http://gapvac.eu/startseite/feed/" />
<link rel='stylesheet' id='contact-form-7-css'  href='http://gapvac.eu/dev/wp-content/plugins/contact-form-7/includes/css/styles.css?ver=3.3.3' type='text/css' media='all' />
<script type='text/javascript' src='http://gapvac.eu/dev/wp-includes/js/jquery/jquery.js?ver=1.8.3'></script>
<link rel="EditURI" type="application/rsd+xml" title="RSD" href="http://gapvac.eu/dev/xmlrpc.php?rsd" />
<link rel="wlwmanifest" type="application/wlwmanifest+xml" href="http://gapvac.eu/dev/wp-includes/wlwmanifest.xml" /> 
<link rel='prev' title='imprint' href='http://gapvac.eu/imprint/' />
<link rel='next' title='clinical development' href='http://gapvac.eu/science/clinical-development/' />
<meta name="generator" content="WordPress 3.5" />
<link rel='canonical' href='http://gapvac.eu/' />
		<script src="http://gapvac.eu/dev/wp-content/themes/gapvac/js/jquery.nivo.slider.pack.js" type="text/javascript"></script>
	</head>
	
	<body class="home page page-id-41 page-template page-template-page-startseite-php">
	
	<div id="container">
		<div id="wrapper" class="container_12">
			
			<div id="header" class="grid_12">
			
				<div id="logo" class="grid_4 alpha">
					<a href="http://gapvac.eu/"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/logo.png" alt="Logo GAPVAC" title="GAPVAC Homepage" /></a>
					<h1 class="texthide">GAPVAC</h1>
					<p class="texthide">Glioma Actively Personalised Vaccine Consortium</p>
				</div>
				
				<div id="header_navigation">
						<ul id="first_navigation" class="menu"><li id="menu-item-20" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-20"><a href="http://gapvac.eu/science/">science</a>
<ul class="sub-menu">
	<li id="menu-item-149" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-149"><a href="http://gapvac.eu/science/apvacs/">APVACs</a></li>
	<li id="menu-item-151" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-151"><a href="http://gapvac.eu/science/objectives/">objectives</a></li>
	<li id="menu-item-150" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-150"><a href="http://gapvac.eu/science/project/">project</a></li>
	<li id="menu-item-152" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-152"><a href="http://gapvac.eu/science/preclinical-development/">preclinical development</a></li>
	<li id="menu-item-153" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-153"><a href="http://gapvac.eu/science/clinical-development/">clinical development</a></li>
</ul>
</li>
<li id="menu-item-21" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-21"><a href="http://gapvac.eu/patients/">patients</a>
<ul class="sub-menu">
	<li id="menu-item-156" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-156"><a href="http://gapvac.eu/patients/the-vaccine/">the vaccine</a></li>
	<li id="menu-item-155" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-155"><a href="http://gapvac.eu/patients/the-study/">the study</a></li>
	<li id="menu-item-154" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-154"><a href="http://gapvac.eu/patients/the-hospitals/">the hospitals</a></li>
</ul>
</li>
<li id="menu-item-22" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-22"><a href="http://gapvac.eu/partners/">partners</a></li>
</ul>						<ul id="second_navigation" class="menu"><li id="menu-item-26" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-26"><a href="http://gapvac.eu/funding/">funding</a></li>
<li id="menu-item-219" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-219"><a href="http://gapvac.eu/news/">news</a>
<ul class="sub-menu">
	<li id="menu-item-382" class="menu-item menu-item-type-taxonomy menu-item-object-category menu-item-382"><a href="http://gapvac.eu/news/status-updates/">status updates</a></li>
</ul>
</li>
<li id="menu-item-24" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-24"><a href="http://gapvac.eu/contact/">contact</a></li>
<li id="menu-item-23" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-23"><a href="http://gapvac.eu/login/">login</a></li>
</ul>				</div><!-- end header_navigation -->
			
			</div><!-- end header -->


			<br class="clear" />			
						
			
			<!-- SLIDER -->
			<div class="slider-wrapper grid_12">
			   	<div id="slider" class="nivoSlider">
								<a href="http://gapvac.eu/the-vaccine/"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/sliderpics/slide-01.jpg" alt="Personalized Immunization" title="<h2>ACTIVELY PERSONALIZED VACCINES</h2>
<p>The vision of<strong> therapeutic cancer vaccines</strong> is to effectively target and destroy all tumor cells while leaving healthy cells unharmed. Current strategies based on target structures on the tumors, i.e. <strong>antigens found commonly in a high proportion of cancer patients</strong>. Recently, several clinical trials showed good safety and promising signs of clinical activity of such cancer vaccines. <strong>GAPVAC is taking cancer vaccines to the next level</strong> by assessing the individuality of each patient´s disease to utilize the full antigenic potential of immunotherapy. GAPVAC`s goal is to deliver to patients a novel class of medicine: <strong>Actively Personalized Vaccines (APVACS)</strong>, which are <strong>actively tailored to the tumor characteristics of each individual patient</strong>.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
" /></a>
								<a href="http://gapvac.eu/patients/the-study/"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/sliderpics/slide-02.jpg" alt="Vaccine Design" title="<h2>PERSONALIZED VACCINE DESIGN</h2>
<p>To generate a vaccine specifically tailored to a single patient<b>, <strong>the disease of the respective patient has to be analyzed</strong></b> prior to treatment. By <b>combining the latest state-of-the-art technologies including next-generation sequencing (NGS), mass spectrometry, computational medicine algorithms,&nbsp;and immunology</b>, our scientists generate a fingerprint of the individual tumor. This fingerprint is aimed to be used by the immune system to selectively destroy cancer cells without harming healthy tissues. In this project, it is planned to design and manufacture a<strong>n Actively Personalized Vaccine (APVAC) for each individual patient within a few months after the initial surgery</strong>.</p></p>
" /></a>
								<a href="http://gapvac.eu/patients/"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/sliderpics/slide-03.jpg" alt="Patients" title="<h2>PATIENTS</h2>
<p><strong>Glioblastoma</strong> is the most aggressive form of brain cancer, unfortunately with only limited therapeutic options and only very poor prognosis. Thus, there is an urgent medical need for new therapeutic approaches. Previous experience in first vaccination trials has indicated encouraging immune responses to vaccinations in these patients.</p>
<p>The <strong>GAPVAC clinical trial</strong> is planned to start in 2014. First, the tumor surgically resected of <strong>newly diagnosed glioblastoma</strong> patients will be analyzed. During this time, patients start their standard therapy (radiochemotherapy). As soon as the personalized vaccine is available, patients will be repeatedly vaccinated on top of the standard therapy.</p>
<p>&nbsp;</p>
" /></a>
								<a href="#"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/sliderpics/slide-04.jpg" alt="Monitoring the Immune System" title="<h2>MONITORING THE IMMUNE SYSTEM</h2>
<p>Patient care and monitoring of the health status of each patient is mandatory in the GAPVAC clinical trial. Apart from this, the latest technologies to analyze the specific immune responses induced by the personalized vaccine will be thoroughly analyzed. Immune responses are monitored in the blood – if possible – also within the tumor of each patient. To assess the biological activity of the novel GAPVAC approach<b>, <strong>immune </strong></b><strong>responses are investigated for each patient before </strong><strong>and </strong><strong>during </strong><strong>vaccination</strong><strong>. </strong></p>
<p><strong></strong></p>
" /></a>
								<a href="http://gapvac.eu/partners/"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/sliderpics/slide-05.jpg" alt="Partners" title="<h2>PARTNERS</h2>
<p><strong>GAPVAC is led by two highly innovative </strong><strong>biotechnology companies</strong><strong> based in Europe:</strong><strong> immatics biotechnologies GmbH</strong> (Coordinator) and <strong>BioNTech AG</strong> (Vice Coordinator) who are dedicated to applying the best science for the benefit of patients. <strong>Ten academic centers in Europe and the US</strong> will recruit patients and collect scientific data for the GAPVAC clinical trial. Academic centers are located in Barcelona (Spain), Copenhagen (Denmark), Geneva (Switzerland), Haifa (Israel), Heidelberg (Germany), Leiden (The Netherlands), Pittsburgh (USA), Southampton (UK) and Tuebingen (Germany). The personalized vaccine will be manufactured at <strong>BCN Peptides</strong> (Barcelona, Spain) and at the <strong>University of Tuebingen</strong> (Tuebingen, Germany). Moreover, results will be disseminated by the <b>Association for Cancer Immunotherapy (<strong>CIMT)</strong></b> who will also contribute to the scientific analysis.</p></p>
" /></a>
								<a href="http://gapvac.eu/funding/"><img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/sliderpics/slide-06.jpg" alt="Funding" title="<h2>FUNDING</h2>
<p>The GAPVAC project is funded by the 7<sup>th</sup> Framework Programme (2012) of the <strong>European Commission </strong>under the “Health” call. About six million EUR will be provided by the EU.</p>
" /></a>
			    </div><!-- slider end -->
			</div><!-- slider-wrapper end -->
			<br class="clear" />
			
			
			<!-- FALLBACK CONTENT -->
			<noscript>
				<div id="noscript_fallback">
						<h2>ACTIVELY PERSONALIZED VACCINES</h2>
<p>The vision of<strong> therapeutic cancer vaccines</strong> is to effectively target and destroy all tumor cells while leaving healthy cells unharmed. Current strategies based on target structures on the tumors, i.e. <strong>antigens found commonly in a high proportion of cancer patients</strong>. Recently, several clinical trials showed good safety and promising signs of clinical activity of such cancer vaccines. <strong>GAPVAC is taking cancer vaccines to the next level</strong> by assessing the individuality of each patient´s disease to utilize the full antigenic potential of immunotherapy. GAPVAC`s goal is to deliver to patients a novel class of medicine: <strong>Actively Personalized Vaccines (APVACS)</strong>, which are <strong>actively tailored to the tumor characteristics of each individual patient</strong>.</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
<p>&nbsp;</p>
						<h2>PERSONALIZED VACCINE DESIGN</h2>
<p>To generate a vaccine specifically tailored to a single patient<b>, <strong>the disease of the respective patient has to be analyzed</strong></b> prior to treatment. By <b>combining the latest state-of-the-art technologies including next-generation sequencing (NGS), mass spectrometry, computational medicine algorithms,&nbsp;and immunology</b>, our scientists generate a fingerprint of the individual tumor. This fingerprint is aimed to be used by the immune system to selectively destroy cancer cells without harming healthy tissues. In this project, it is planned to design and manufacture a<strong>n Actively Personalized Vaccine (APVAC) for each individual patient within a few months after the initial surgery</strong>.</p></p>
						<h2>PATIENTS</h2>
<p><strong>Glioblastoma</strong> is the most aggressive form of brain cancer, unfortunately with only limited therapeutic options and only very poor prognosis. Thus, there is an urgent medical need for new therapeutic approaches. Previous experience in first vaccination trials has indicated encouraging immune responses to vaccinations in these patients.</p>
<p>The <strong>GAPVAC clinical trial</strong> is planned to start in 2014. First, the tumor surgically resected of <strong>newly diagnosed glioblastoma</strong> patients will be analyzed. During this time, patients start their standard therapy (radiochemotherapy). As soon as the personalized vaccine is available, patients will be repeatedly vaccinated on top of the standard therapy.</p>
<p>&nbsp;</p>
						<h2>MONITORING THE IMMUNE SYSTEM</h2>
<p>Patient care and monitoring of the health status of each patient is mandatory in the GAPVAC clinical trial. Apart from this, the latest technologies to analyze the specific immune responses induced by the personalized vaccine will be thoroughly analyzed. Immune responses are monitored in the blood – if possible – also within the tumor of each patient. To assess the biological activity of the novel GAPVAC approach<b>, <strong>immune </strong></b><strong>responses are investigated for each patient before </strong><strong>and </strong><strong>during </strong><strong>vaccination</strong><strong>. </strong></p>
<p><strong></strong></p>
						<h2>PARTNERS</h2>
<p><strong>GAPVAC is led by two highly innovative </strong><strong>biotechnology companies</strong><strong> based in Europe:</strong><strong> immatics biotechnologies GmbH</strong> (Coordinator) and <strong>BioNTech AG</strong> (Vice Coordinator) who are dedicated to applying the best science for the benefit of patients. <strong>Ten academic centers in Europe and the US</strong> will recruit patients and collect scientific data for the GAPVAC clinical trial. Academic centers are located in Barcelona (Spain), Copenhagen (Denmark), Geneva (Switzerland), Haifa (Israel), Heidelberg (Germany), Leiden (The Netherlands), Pittsburgh (USA), Southampton (UK) and Tuebingen (Germany). The personalized vaccine will be manufactured at <strong>BCN Peptides</strong> (Barcelona, Spain) and at the <strong>University of Tuebingen</strong> (Tuebingen, Germany). Moreover, results will be disseminated by the <b>Association for Cancer Immunotherapy (<strong>CIMT)</strong></b> who will also contribute to the scientific analysis.</p></p>
						<h2>FUNDING</h2>
<p>The GAPVAC project is funded by the 7<sup>th</sup> Framework Programme (2012) of the <strong>European Commission </strong>under the “Health” call. About six million EUR will be provided by the EU.</p>
				</div><!-- end noscript_fallback -->
			</noscript>
			
						
			
			
			<!-- NEWS SECTION -->
			<div id="news-section" class="grid_7">
				<h2>News</h2>
				<ul>
											<li><span>Sep 25, 2015:&nbsp;</span><a href="http://gapvac.eu/ten-patients-enrolled-in-gapvac-101-clinical-trial/" title="Ten patients enrolled in GAPVAC-101 clinical trial">Ten patients enrolled in GAPVAC-101 clinical trial</a></li>
												<li><span>Jul 27, 2015:&nbsp;</span><a href="http://gapvac.eu/first-apvac2-successfully-vaccinated/" title="First APVAC2 successfully vaccinated!">First APVAC2 successfully vaccinated!</a></li>
													</ul>
			</div><!-- end news-section -->	
			
			<!-- SOCIAL SECTION -->
			<div id="social-section" class="grid_3 suffix_2 omega">
				<h2>Social</h2>
				<img src="http://gapvac.eu/dev/wp-content/themes/gapvac/style/images/twitter.png" alt="Follow immatics on Twitter" title="Follow immatics on Twitter" /><a href="https://twitter.com/gapvac/" title="Follow immatics on Twitter" target="_blank">Follow us on Twitter</a>
			</div><!-- end social-section -->
			<br class="clear" />
			
			
						
			<script type='text/javascript' src='http://gapvac.eu/dev/wp-content/plugins/contact-form-7/includes/js/jquery.form.min.js?ver=3.25.0-2013.01.18'></script>
<script type='text/javascript'>
/* <![CDATA[ */
var _wpcf7 = {"loaderUrl":"http:\/\/gapvac.eu\/dev\/wp-content\/plugins\/contact-form-7\/images\/ajax-loader.gif","sending":"Senden ..."};
/* ]]> */
</script>
<script type='text/javascript' src='http://gapvac.eu/dev/wp-content/plugins/contact-form-7/includes/js/scripts.js?ver=3.3.3'></script>

 </div><!-- end wrapper -->
 <br class="clear" />
 
 <div id="footer_outer">
 	<div id="footer_inner">
			<div class="menu-footer-menu-container"><ul id="menu-footer-menu" class="menu"><li id="menu-item-40" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-40"><a href="http://gapvac.eu/imprint/">imprint</a></li>
</ul></div>		</div><!-- end footer_inner -->
	</div> <!-- end footer_outer -->

</div><!-- end container -->
		 
	</body>
     
	
<script type="text/javascript">
			jQuery(window).load(function() {
   	jQuery('#slider').nivoSlider({
        effect: 'slideInLeft', // Specify sets like: 'fold,fade,sliceDown'
        animSpeed: 250, // Slide transition speed
        pauseTime: 30000, // How long each slide will show
        startSlide: 0, // Set starting Slide (0 index)
        directionNav: true, // Next & Prev navigation
        controlNav: true, // 1,2,3... navigation
        controlNavThumbs: false, // Use thumbnails for Control Nav
        pauseOnHover: true, // Stop animation while hovering
        manualAdvance: false, // Force manual transitions
        prevText: '« previous', // Prev directionNav text
        nextText: 'next »', // Next directionNav text
        randomStart: false, // Start on a random slide
        beforeChange: function(){}, // Triggers before a slide transition
        afterChange: function(){}, // Triggers after a slide transition
        slideshowEnd: function(){}, // Triggers after all slides have been shown
        lastSlide: function(){}, // Triggers when last slide is shown
        afterLoad: function(){} // Triggers when slider has loaded
				});
		});
</script>

</html>